BIOAGE LABS
BIOAGE discovers and develops drugs to treat aging and associated diseases.
BIOAGE LABS
Industry:
Biotechnology Computer
Founded:
2015-01-01
Address:
Richmond, California, United States
Country:
United States
Website Url:
http://www.bioagelabs.com
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
123.9 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF Google Font API Mobile Non Scaleable Content IPv6 Google Apps For Business Microsoft Azure DNS Cloudflare JS CDN JS
Similar Organizations
Editas Medicine
Editas Medicine is engaged in discovering and developing a novel class of genome editing therapeutics.
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
KayoThera
KayoThera develops therapeutics used to cure late-stage and metastatic cancers.
KSQ Therapeutics
KSQ Therapeutics is using CRISPR technology within a powerful drug discovery engine to enable high-confidence drug development.
METiS Therapeutics
METiS Therapeutics uses integrated drug discovery to develop medicines in a variety of illness areas.
Nutcracker Therapeutics
Nutcracker Therapeutics is a biotech company that develops mRNA therapeutics.
Pliant Therapeutics
Pliant Therapeutics focuses on discovering, developing, and commercializing breakthrough treatments for fibrotic diseases.
Scholar Rock
Scholar Rock is a biopharmaceutical company that develops and discovers new medicines and treatments for the serious diseases.
Current Advisors List
Current Employees Featured
Founder
Investors List
sanem fabri
sanem fabri investment in Series C - BIOAGE LABS
Felicis Ventures
Felicis Ventures investment in Series C - BIOAGE LABS
Caffeinated Capital
Caffeinated Capital investment in Series C - BIOAGE LABS
Ling Wong
Ling Wong investment in Series C - BIOAGE LABS
Redpoint
Redpoint investment in Series C - BIOAGE LABS
AME Cloud Ventures
AME Cloud Ventures investment in Series C - BIOAGE LABS
Pear VC
Pear VC investment in Series C - BIOAGE LABS
Bossanova Investimentos
Bossanova Investimentos investment in Series C - BIOAGE LABS
Kaiser Foundation Hospitals
Kaiser Foundation Hospitals investment in Series C - BIOAGE LABS
Andreessen Horowitz
Andreessen Horowitz investment in Series C - BIOAGE LABS
Key Employee Changes
| Date | New article |
|---|---|
| 2021-11-17 | BioAge appoints Dov Goldstein as Chief Financial Officer and Ann Neale as Chief Development Officer |
Official Site Inspections
http://www.bioagelabs.com
- Host name: 199.36.158.100
- IP address: 199.36.158.100
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "BIOAGE LABS"
BioAge Labs | Company
Our broader vision. We envision a future where aging is decoupled from disease and disability—a future in which growing older allows us to pursue our goals, accumulate new experiences and accomplishments, and actively contribute to …See details»
Investor Relations | BioAge Labs, Inc.
Nov 4, 2024 BioAge Labs, Inc. Investor relations (IR) website contains information about our business for stockholders, potential investors, and financial analysts.See details»
BioAge Labs - Crunchbase Company Profile
Contact Email [email protected] BIOAGE discovers and develops drugs to treat aging and associated diseases. The company's primary initiative, azelaprag, is an oral APJ agonist on track for Phase 2 trials in conjunction with tirzepatide …See details»
BioAge Labs - LinkedIn
BioAge Labs | 14,790 followers on LinkedIn. We are harnessing the biology of human aging to develop novel targets and therapies for metabolic diseases. | BioAge is a clinical-stage biotechnology ...See details»
BioAge Labs Announces Inaugural Scientific Advisory …
May 16, 2024 Newly appointed advisors are world-renowned experts in obesity, diabetes, and cardiometabolic diseases, spanning basic biology to late-stage development RICHMOND, …See details»
Press Releases | BioAge Labs, Inc.
Oct 1, 2024 Trial to evaluate weight loss efficacy of azelaprag, an oral small molecule apelin receptor agonist that mimics key biological effects of exercise STRIDES is being conducted in …See details»
BioAge Announces First Patient Dosed in the STRIDES …
RICHMOND, Calif., July 29, 2024--BioAge Labs, Inc., ("BioAge"), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases …See details»
BioAge Labs Reports Third Quarter 2024 Financial Results …
Nov 7, 2024 Third Quarter 2024 Financial Results. Research and development expenses were $20.0 million for the quarter ended September 30, 2024, compared to $6.5 million for the same …See details»
BioAge Partners With Age Labs to Decipher …
Aug 24, 2022 BioAge Labs, Inc. (“BioAge”, “the Company”), a biotechnology company developing therapeutics that target the molecular causes of aging to extend healtSee details»
BioAge Labs | About us - Discovery
Our leadership team has diverse professional experience across the biopharma ecosystem and an established track record of success, involved in 95+ regulatory approvals.See details»
BioAge Labs Announces Plans for Phase 2 Trial of First-in …
Oct 26, 2023 Chorus , an operationally independent clinical development organization within Eli Lilly and Company (“Lilly”) dedicated to working with biotechs to develop their assets from …See details»
BioAge Labs Announces Plans for Phase 2 Trial of BGE …
Oct 26, 2023 Chorus, an operationally independent clinical development organization within Eli Lilly and Company (“Lilly”) dedicated to working with biotechs to develop their assets from …See details»
BioAge Labs | Extending healthy lifespan
Feb 13, 2024 BioAge Labs Announces Plans for Phase 2 Trial of First-in-Class Apelin Receptor Agonist BGE-105/Azelaprag Co-Administered With Tirzepatide for Treatment of Obesity, in …See details»
BioAge Raises $90M to Treat Aging and Age-related …
Mar 12, 2020 Proceeds will support advancement of the company’s pipeline and proprietary platform for identifying and developing therapies to treat diseases of agingSee details»
Release Details - ir.bioagelabs.com
STRIDES is being conducted in collaboration with Eli Lilly and Company’s (Lilly) Chorus clinical development organization. Lilly is providing tirzepatide for the trial . A second planned Phase 2 …See details»
BioAge Labs (Nasdaq:BIOA) - Simply Wall St
4 days ago bioagelabs.com: BioAge Labs, Inc. is a clinical-stage biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company’s …See details»
BioAge Labs | About Aging - Discovery
BioAge is focused on deciphering the. molecular mechanisms that increase human. healthspan and lifespan. BioAge is focused on deciphering the. molecular mechanisms that increaseSee details»
BioAge Announces First Cohort Dosed in Phase 1b
Apr 19, 2022 BioAge Labs, Inc., a biotechnology company developing therapeutics that target the molecular causes of aging to extend healthy human lifespan, today aSee details»
BioAge Labs | Platform - Discovery
BioAge’s human-first platform identifies novel metabolic aging targets by analyzing proprietary longitudinal human samples and detailed health records spanning 45+ years.See details»